Lineage Cell Therapeutics, Inc.·Healthcare

AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned

Defender Capital LLC. bought a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,829,099 shares of the company's stock, valued at approximately $11,405,000. Lineage Cell Therapeutics comprises approximately 3.7%

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline with the launch of COR1, a new corneal endothelial cell (CEnC) therapy program, in preclinical development for the treatment of corneal endothelial disease. Corneal endothelial disease is a progressive,.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a longer cash runway following recent warrant exercises, progress in manufacturing capabilities, and early internal validation work in a newly launched islet cell research initiative. Management also reviewed updates across its three most visible programs-OpRegen in geographic atrophy, OPC1 in spinal cord injury, and

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Lineage Cell (LCTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.01 per share a year ago.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Healthcare
Biotechnology
70
1992-03-05
1.80